| Title |
Differences in Adverse Effect Reporting in Placebo Groups in SSRI and Tricyclic Antidepressant Trials
|
|---|---|
| Published in |
Drug Safety, November 2012
|
| DOI | 10.2165/11316580-000000000-00000 |
| Pubmed ID | |
| Authors |
Winfried Rief, Yvonne Nestoriuc, Anna von Lilienfeld-Toal, Imis Dogan, Franziska Schreiber, Stefan G. Hofmann, Arthur J. Barsky, Jerry Avorn |
| Abstract |
Biases in adverse effect reporting in randomized controlled trials (RCTs) [e.g. due to investigator expectations or assessment quality] can be quantified by studying the rates of adverse events reported in the placebo arms of such trials. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 3 | 75% |
| Unknown | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 75% |
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 124 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 2 | 2% |
| Denmark | 1 | <1% |
| Unknown | 121 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 27 | 22% |
| Student > Master | 18 | 15% |
| Student > Bachelor | 18 | 15% |
| Student > Ph. D. Student | 11 | 9% |
| Student > Doctoral Student | 10 | 8% |
| Other | 22 | 18% |
| Unknown | 18 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Psychology | 39 | 31% |
| Medicine and Dentistry | 32 | 26% |
| Neuroscience | 9 | 7% |
| Agricultural and Biological Sciences | 7 | 6% |
| Nursing and Health Professions | 5 | 4% |
| Other | 7 | 6% |
| Unknown | 25 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 25. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 December 2020.
All research outputs
#1,546,566
of 25,374,647 outputs
Outputs from Drug Safety
#143
of 1,852 outputs
Outputs of similar age
#12,720
of 285,244 outputs
Outputs of similar age from Drug Safety
#44
of 812 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,852 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.9. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 285,244 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 812 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.